Develops cancer treatments using immune system cells.
Jun 2026Revenue $431M/yrExpenses $453M/yr
Expected break-even Mar 2027Cash runway over 10 years from Jun 2026
Figures by year
When will Immunocore Holdings be profitable?
Its revenue and expense trends are projected to cross in Mar 2027. In the 12 months to Jun 2026, revenue was $431M and expenses $453M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $400M | $445M | −$45.4M |
| Dec 2024 | $310M | $381M | −$70.5M |
| Dec 2023 | $249M | $309M | −$59.6M |
| Dec 2022 | $174M | $226M | −$51.7M |
| Dec 2021 | $4.08M | $179M | −$175M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.